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Letter to the Editor 
Efficacy of vancomycin plus levofloxacin combination 
therapy for refractory pericarditis due to multiresistant 
Streptococcus pneumoniae 
Amar Safdar(172) 
Int J Infect Dis 2003; 7: 287 
Antimicrobial combination therapy with vancomycin 
has been suggested for patients with life-threatening 
non-pulmonary infections due to multiresistant Strepto- 
coccus pneumonia1 I present a case of fulminant 
pericarditis due to penicillin-resistant S. pneumoniae 
that was refractory to standard antimicrobial therapy. 
A 29-year-old HIV-seronegative man from Florida 
was admitted to a hospital in South Carolina because of 
severe anterior chest pain and acute respiratory distress. 
He had suffered from febrile cough and generalized 
malaise for nearly a week prior to admission. Faint heart 
sounds, left lower-lobe consolidation and echocardio- 
graphic evidence of pericardial effusion and cardiac 
tamponade (diastolic equalization of intraventricular 
pressure) were present. The white cell count was 
10 400/mm3, serum aminotransferase levels were 
elevated (alanine aminotransferase 546 U/L, aspartate 
aminotransferase 491 U/L), and the erythrocyte sedi- 
mentation rate was 110 mm/h. Prominent intragranulo- 
cytic Gram-positive diplococci were present in turbid, 
brown pericardial fluid (360 mL). The antimicrobial 
susceptibility of S. pneumoniae isolated from pericardial 
fluid and blood was as follows: penicillin 4 mg/mL; 
ceftriaxone 3 mg/mL; erythromycin ~21 mm; rifampin 
>19 mm; vancomycin <17 mm; levofloxacin <17 mm; line- 
zolid 28 mm; and quinupristin-dalfopristin 18 mm. For 
the first two antibiotics, the microdilution assay was used; 
for the remainder, the disk diffusion assay was used. 
On the second hospital day, vancomycin (2 g daily) 
was added to ceftriaxone (4 g daily). On the fifth 
hospital day, the white cell count rose to 16 lOO/mmj; 
fever persisted (>39”C), and purulent pericardial 
drainage (>120 ml/day) remained unchanged. The 
patient was treated with quinupristin-dalfopristin 
(7.5 mg/kg every 8 h), and ceftriaxone was discontinued. 
On the ninth day of hospitalization, he became hypo- 
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tensive, he remained febrile (>4O”C), and the white cell 
count was 31 800/mm3. Pericardial fluid still showed 
intracellular Gram-positive diplococci. Levofloxacin 
(750 mg intravenous, daily)2 was added to vancomycin. 
Twenty-four hours later, fever (<39OC) and leukocytosis 
(~25 000/mm3) started to improve. On the following day, 
the patient underwent pericardectomy. Combined 
antimicrobials were given for 7 days, and were tolerated 
with no significant untoward effects. 
The emergence of penicillin- and extended- 
spectrum cephalosporin-resistant pneumococci has led 
to considerable interest in exploring antimicrobial 
combination therapy. 1,3 The presence of significant in 
vitro synergy (time-kill method) between levofloxacin 
and vancomycin against clinical isolates of penicillin- 
resistant S. pneumoniae was encouraging.3 It is, however, 
important to realize that certain drug combinations may 
compromise antimicrobial efficacy, such as treatment 
with levofloxacin plus rifampin, which should be 
avoided due to drug antagonism.3,4 This case demon- 
strates that high-dose levofloxacin in combination with 
vancomycin was well tolerated and appeared to be 
efficacious in a patient with refractory multiresistant 
pneumococcal pericarditis. Further clinical validation is 
needed before routine use is suggested. 
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